Skip to main content

02.05.2024 | Original Paper

Beta blockers are associated with lower all-cause mortality among HFpEF patients

verfasst von: Joseph Ibrahim, Carly Fabrizio, Ahmet Sezer, Floyd Thoma, Brenden Boyle, Suresh R. Mulukutla, Jessica H. Huston, Marc A. Simon, Gavin W. Hickey

Erschienen in: Clinical Research in Cardiology

Einloggen, um Zugang zu erhalten

Abstract

Background

The evidence regarding beta blocker (BB) benefit in heart failure with preserved ejection fraction (HFpEF) remains inconclusive, leading to consideration of BB withdrawal in this population.

Objectives

In this study, we retrospectively analyzed the association of BB on all-cause mortality in HFpEF patients.

Methods

This is a single-center retrospective cohort study of 20,206 patients with left ventricular ejection fraction (EF) ≥ 50% who were hospitalized with decompensated HF between January 2011 and March 2020. Survival is reported at 30 days, 1 year, and 3 years. A secondary analysis comparing mortality for patients on BB with additional indications including hypertension (HTN), coronary artery disease (CAD), and atrial fibrillation (AF) was completed. Mortality was compared between patients on BB and additional therapies of spironolactone or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs).

Results

BB showed lower all-cause mortality at 30 days, 1 year, and 3 years (p < 0.0001). This association with lower all-cause mortality was validated by a supplementary propensity score–matched analysis. At 3 years, there was significant mortality reduction with addition of BB to either spironolactone (p = 0.0359) or ACEi/ARBs (p < 0.0001).

Conclusion

In a large single-center retrospective registry, BB use was associated with lower mortality in HFpEF patients with a recent decompensated HF hospitalization. The mortality benefit persisted in those treated with spironolactone or ACEi/ARBs, and in those with AF. This provocative data further highlights the uncertainty of the benefit of BB use in this cohort and calls for re-consideration of BB withdrawal, especially in those tolerating it well, without conclusive, large, and randomized trials showing lack of benefit or harm.

Graphical Abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D (1999) Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33(7):1948–1955CrossRefPubMed Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D (1999) Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33(7):1948–1955CrossRefPubMed
2.
Zurück zum Zitat Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R et al (2000) Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 86(10):1090–1096CrossRefPubMed Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R et al (2000) Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 86(10):1090–1096CrossRefPubMed
3.
Zurück zum Zitat Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G et al (2001) Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 87(4):413–9CrossRefPubMed Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G et al (2001) Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 87(4):413–9CrossRefPubMed
4.
Zurück zum Zitat Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895–e1032. https://doi.org/10.1161/CIR.0000000000001063 Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895–e1032. https://​doi.​org/​10.​1161/​CIR.​0000000000001063​
5.
Zurück zum Zitat Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K et al (2004) Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 25(14):1214–20CrossRefPubMed Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K et al (2004) Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 25(14):1214–20CrossRefPubMed
6.
Zurück zum Zitat Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47(1):76–84CrossRefPubMed Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47(1):76–84CrossRefPubMed
7.
Zurück zum Zitat Gevaert AB, Kataria R, Zannad F, Sauer AJ, Damman K, Sharma K et al (2022) Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart 108(17):1342–1350CrossRefPubMed Gevaert AB, Kataria R, Zannad F, Sauer AJ, Damman K, Sharma K et al (2022) Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart 108(17):1342–1350CrossRefPubMed
8.
Zurück zum Zitat Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338–2345CrossRefPubMed Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338–2345CrossRefPubMed
9.
Zurück zum Zitat Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456–2467CrossRefPubMed Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456–2467CrossRefPubMed
10.
Zurück zum Zitat Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392CrossRefPubMed Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392CrossRefPubMed
11.
Zurück zum Zitat Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609–1620CrossRefPubMed Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609–1620CrossRefPubMed
12.
Zurück zum Zitat Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777–781CrossRefPubMed Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777–781CrossRefPubMed
13.
Zurück zum Zitat Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334(21):1349–1355CrossRefPubMed Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334(21):1349–1355CrossRefPubMed
14.
Zurück zum Zitat CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet 353(9146):9–13CrossRef CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet 353(9146):9–13CrossRef
15.
Zurück zum Zitat MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). The Lancet 353(9169):2001–2007CrossRef MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). The Lancet 353(9169):2001–2007CrossRef
16.
Zurück zum Zitat Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS et al (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26–35CrossRefPubMed Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS et al (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26–35CrossRefPubMed
17.
Zurück zum Zitat van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M et al (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53(23):2150–2158CrossRefPubMed van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M et al (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53(23):2150–2158CrossRefPubMed
18.
Zurück zum Zitat Kobayashi M, Machida N, Mitsuishi M, Yamane Y (2004) β-Blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 17(12):1112–1119CrossRefPubMed Kobayashi M, Machida N, Mitsuishi M, Yamane Y (2004) β-Blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 17(12):1112–1119CrossRefPubMed
19.
Zurück zum Zitat Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Miwa T et al (2008) Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 10(5):446–453CrossRefPubMed Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Miwa T et al (2008) Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 10(5):446–453CrossRefPubMed
20.
Zurück zum Zitat Silverman DN, Plante TB, Infeld M, Callas PW, Juraschek SP, Dougherty GB et al (2019) Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT Trial. JAMA Network Open 2(12):e1916598CrossRefPubMedPubMedCentral Silverman DN, Plante TB, Infeld M, Callas PW, Juraschek SP, Dougherty GB et al (2019) Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT Trial. JAMA Network Open 2(12):e1916598CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Fu EL, Uijl A, Dekker FW, Lund LH, Savarese G, Carrero JJ (2020) Association between & #x3b2;-blocker use and mortality/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease. Circulation: Heart Failure. 13(11):e007180PubMed Fu EL, Uijl A, Dekker FW, Lund LH, Savarese G, Carrero JJ (2020) Association between & #x3b2;-blocker use and mortality/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease. Circulation: Heart Failure. 13(11):e007180PubMed
22.
Zurück zum Zitat Palau P, Seller J, Domínguez E, Sastre C, Ramón Jose M, de La Espriella R et al (2021) Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol 78(21):2042–2056CrossRefPubMed Palau P, Seller J, Domínguez E, Sastre C, Ramón Jose M, de La Espriella R et al (2021) Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol 78(21):2042–2056CrossRefPubMed
23.
Zurück zum Zitat Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304(14):801–807CrossRef Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304(14):801–807CrossRef
24.
Zurück zum Zitat Hjalmarson A, Herlitz J, Holmberg S, Rydén L, Swedberg K, Vedin A et al (1983) The Göteborg Metoprolol Trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67(6 Pt 2):I26-32PubMed Hjalmarson A, Herlitz J, Holmberg S, Rydén L, Swedberg K, Vedin A et al (1983) The Göteborg Metoprolol Trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67(6 Pt 2):I26-32PubMed
25.
Zurück zum Zitat Chadda K, Goldstein S, Byington R, Curb JD (1986) Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73(3):503–510CrossRefPubMed Chadda K, Goldstein S, Byington R, Curb JD (1986) Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73(3):503–510CrossRefPubMed
26.
Zurück zum Zitat Freemantle N, Cleland J, Young P, Mason J, Harrison J (1999) β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318(7200):1730–1737CrossRefPubMedPubMedCentral Freemantle N, Cleland J, Young P, Mason J, Harrison J (1999) β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318(7200):1730–1737CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat He Y, Ling Y, Guo W, Li Q, Yu S, Huang H et al (2021) Prevalence and prognosis of HFimpEF developed from patients with heart failure with reduced ejection fraction: systematic review and meta-analysis. Front Cardiovasc Med 8:757596CrossRefPubMedPubMedCentral He Y, Ling Y, Guo W, Li Q, Yu S, Huang H et al (2021) Prevalence and prognosis of HFimpEF developed from patients with heart failure with reduced ejection fraction: systematic review and meta-analysis. Front Cardiovasc Med 8:757596CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Mainor AJ, Morden NE, Smith J, Tomlin S, Skinner J (2019) ICD-10 coding will challenge researchers: caution and collaboration may reduce measurement error and improve comparability over time. Med Care 57(7):e42–e46CrossRefPubMedPubMedCentral Mainor AJ, Morden NE, Smith J, Tomlin S, Skinner J (2019) ICD-10 coding will challenge researchers: caution and collaboration may reduce measurement error and improve comparability over time. Med Care 57(7):e42–e46CrossRefPubMedPubMedCentral
Metadaten
Titel
Beta blockers are associated with lower all-cause mortality among HFpEF patients
verfasst von
Joseph Ibrahim
Carly Fabrizio
Ahmet Sezer
Floyd Thoma
Brenden Boyle
Suresh R. Mulukutla
Jessica H. Huston
Marc A. Simon
Gavin W. Hickey
Publikationsdatum
02.05.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-024-02451-0

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.